Aikawa Yoshiyuki 4

What Happened
Yoshiyuki Aikawa, a reported >10% owner of SBC Medical Group Holdings, sold the economic equivalent of 4,422,900 SBC shares on March 6, 2026. The Form 4 shows a per-share price of $2.12 and total proceeds of $9,376,548. The transaction reflects the sale of shares of Aikawa Equity Management Co., Ltd. (AEM) that correspond to SBC shares — no actual SBC shares were directly sold by Aikawa or AEM.

Key Details

• Transaction date: March 6, 2026; Form 4 filed March 10, 2026 (filed within the standard two business‑day window).
• Reported sale: 4,422,900 SBC-equivalent shares at $2.12 per share; proceeds reported $9,376,548 (price derived from AEM share price in JPY and converted to USD per footnote).
• Derivative/other entries: Two "J" (other acquisition/disposition) entries report 44,229 units each (these correspond to 44,229 AEM shares × 100 = 4,422,900 SBC shares) tied to the AEM share transactions and related contractual rights.
• Shares owned after transaction: the filing reports Aikawa indirectly beneficially owns 861,600 SBC shares through AEM (per footnote). Aikawa no longer controls AEM and disclaims beneficial ownership of AEM-held SBC shares except to the extent of any pecuniary interest.
• Important contract notes (from footnotes): consultants who bought AEM shares have a potential redemption right if SBC falls below a threshold after April 1, 2029; Aikawa retains a conditional repurchase right to buy back AEM shares at the same purchase price upon satisfaction of certain conditions.
• Price conversion: sale price is based on AEM price (JPY 33,417 per AEM share), divided by 100, then converted to USD at JPY 157.640 = US$1 (Fed rate reported Mar 9, 2026).

Context
This was effectively a sale of shares in AEM that correspond to SBC common stock rather than a direct open-market sale of SBC shares. For retail investors: sales by large/10% owners can reflect structural or entity-level transfers and contractual arrangements (here, transfer to consultants and retained repurchase/redemption rights) rather than a simple insider cash‑out. Purchases generally carry stronger signals of insider confidence; this filing documents a complex, structured disposition with follow-on contractual terms rather than a routine direct sale of company stock.